~~<i id='02CF289B1C'><strike id='02CF289B1C'><tt id='02CF289B1C'><pre id='02CF289B1C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：hotspot 2025-08-11 07:59:04 - browse：2388

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Listen: BridgeBio's big week & Lilly's Alzheimer's data

focus

knowledge

leisure time

focus

hotspot

1:50HughJackmanandRyanReynoldsattendTheAdamProjectWorldPremiereatAliceTullyHall,Feb.28,2022,inNewYor

WSS

Listen: BridgeBio's big week & Lilly's Alzheimer's data

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Why the advice to take all your antibiotics may be wrong

White House announces new plan to address the growing threat of xylazine in overdose crisis

Reframing the conversation around gain

leisure time

Wikipedia

focus

New air purifier tech could be key to improving indoor air quality

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Dobbs anniversary: the lost opportunity of abortion as health care

New chart reveals military’s vast involvement in Operation Warp Speed

United colonoscopy coverage change 'may cost lives,' doctors say

New chart reveals military’s vast involvement in Operation Warp Speed

How to save PrEP access — and even expand it

A new deal aims to ramp up use of AI in rehab care decisions

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

It's time to take a new tack for treating Alzheimer's

knowledge

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

A new deal aims to ramp up use of AI in rehab care decisions

How Brent Saunders' Allergan experiment failed

'The View' co

New chart reveals military’s vast involvement in Operation Warp Speed

knowledge

leisure time

focus

hotspot